Understanding how immune evasion occurs in high-risk myelodysplastic syndrome
VISTA-Mediated Immune Evasion in High-Risk Myelodysplastic Syndrome
This study is looking at how a protein called VISTA helps high-risk myelodysplastic syndrome (HR-MDS) avoid being attacked by the immune system, with the goal of finding new ways to improve treatments for patients like you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-11069224 on NIH RePORTER |
What this research studies
This research investigates the immune mechanisms that allow high-risk myelodysplastic syndrome (HR-MDS) to evade the body's immune response. It focuses on the role of a specific protein called VISTA, which suppresses T cell activation and contributes to immune suppression in HR-MDS. By studying the immune profiles of patients with HR-MDS, the research aims to identify new therapeutic targets that could enhance the effectiveness of existing treatments. The approach includes analyzing immune cell populations and their interactions in the context of HR-MDS.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with high-risk myelodysplastic syndrome who may benefit from novel immunotherapeutic approaches.
Not a fit: Patients with low-risk myelodysplastic syndrome or those without any form of myelodysplastic syndrome may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with high-risk myelodysplastic syndrome, potentially enhancing their immune response against the disease.
How similar studies have performed: Previous research has shown that targeting immune checkpoints can be effective in other hematologic malignancies, suggesting potential for success in this area as well.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Zhang, Raymond J — Vanderbilt University
- Study coordinator: Zhang, Raymond J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.